Erasca reports 23% response rate in RAS/MAPK-altered non-CRC tumors; combo trial in H1 2023

Erasca, Inc.

23% (6/26) of RAS/MAPK-altered non-CRC solid tumor patients responded to single-agent ERAS-007 or ERAS-601.
44% (4/9) of BRAF-driven non-CRC solid tumor patients responded (1 confirmed PR, 3 unconfirmed PRs).
Favorable safety profiles with largely non-overlapping, manageable treatment-related adverse events.
Company plans to initiate ERAS-007 + ERAS-601 (MAPKlamp) dose escalation trial in first half of 2023.
Retrospective pooled analysis included HERKULES-1, FLAGSHP-1, and ASN007-101 trials with data cutoffs through July 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.